

CAR-T Cell Clinical Trial in Autoimmune Diseases

A Study of FT819 in B-cell Mediated Autoimmune Diseases



What is FT819?

An investigational cell therapy made from cells of a single healthy donor

An "off-the-shelf" product, ready for immediate use

FT819 is engineered to find specific B cells in your body and eliminate them

What do we know?



Studies have shown that CAR-T cell therapy targets B cells in patients with severe lupus, vasculitis, myositis, and scleroderma





Patients that respond to approved CAR-T cell therapy have shown significant improvement in their health and daily lives



FT819 has been well tolerated in the treatment of over 50 patients with B cell malignancies

Why OUR study?

Fate's "off-the-shelf" CAR-T program



More Information
www.clinicaltrials.gov (NCT#06308978)

